3-pyridin-3-yl-1,5-diazatricyclo[5.2.2.0<2,6>]undecane | 927875-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-pyridin-3-yl-1,5-diazatricyclo[5.2.2.0<2,6>]undecane
• 英文别名: 3-Pyridin-3-yl-1,5-diazatricyclo[5.2.2.02,6]undecane
• CAS: 927875-77-2
• 化学式: C₁₄H₁₉N₃
• 分子量: 229.325
• InChiKey: OUSWGZBGFGZRKB-UHFFFAOYSA-N

物化性质

• 沸点：
  383.9±27.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-pyridin-3-yl-1,5-diazatricyclo[5.2.2.0<2,6>]undecane 、 3,4-二氯苯异氰酸酯 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 5-(N-(3,4-dichlorophenyl)carbamoyl)-3-pyridin-3-yl-1,5-diazatricyclo[5.2.2.2.0<2,6>]undecane
  参考文献：
  名称：

  WO2007/24814

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(1-(3-Pyridinyl)-2-nitroethyl)-1-azabicyclo[2.2.2]octan-3-one 在 Raney nickel 氢气 作用下， 反应 48.0h， 以67%的产率得到3-pyridin-3-yl-1,5-diazatricyclo[5.2.2.0<2,6>]undecane
  参考文献：
  名称：

  WO2007/24814

  摘要：

  公开号：

文献信息

• Heteroaryl-Substituted Diazatricycloalkanes and Methods of Use Thereof
  申请人：Mazurov Anatoly

  公开号：US20070197579A1

  公开（公告）日：2007-08-23

  The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the α7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the α7 nAChR subtype. The diazatricycloalkanes typically consist of a 1-azabicyclooctane fused to pyrrolidine ring. The substitutent heteroaryl groups are 5- or 6-membered ring heteroaromatics, such as 3-pyridinyl and 5-pyrimidinyl moieties, which are attached directly to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine moiety is substituted with an arylcarbonyl (amide type derivative) or an arylaminocarbonyl (N-arylcarbamoyl) (urea type derivative) group. The compounds are beneficial in therapeutic applications requiring a selective interaction at certain nAChR subtypes. That is, the compounds modulate the activity of certain nAChR subtypes, particularly the α7 nAChR subtype, and do not have appreciable activity toward muscarinic receptors. Radiolabeled versions of the compounds can be used in diagnostic methods.

  本发明涉及杂环取代的二氮杂三环烷的酰胺和脲衍生物、包括这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。更具体地说，治疗方法涉及通过给予一种或多种化合物来调节α7 nAChR亚型的活性，以治疗或预防由α7 nAChR亚型介导的疾病。二氮杂三环烷通常由1-氮杂双环辛烷与吡咯烷环融合而成。取代杂环基团是5-或6-成员环杂芳基，例如3-吡啶基和5-嘧啶基，直接连接到二氮杂三环烷上。吡咯烷基团的次要氮原子被芳基羰基（酰胺型衍生物）或芳基氨基羰基（N-芳基氨基甲酰）（脲型衍生物）基团取代。这些化合物在需要选择性相互作用于某些nAChR亚型的治疗应用中具有益处。也就是说，这些化合物调节某些nAChR亚型的活性，特别是α7 nAChR亚型，并且对于肌动蛋白受体没有明显的活性。这些化合物的放射标记版本可用于诊断方法。
• HETEROARYL-SUBSTITUTED DIAZATRICYCLOALKANES AND METHODS OF USE THEREOF
  申请人：Mazurov Anatoly

  公开号：US20100197720A1

  公开（公告）日：2010-08-05

  The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the α7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the α7 nAChR subtype. The diazatricycloalkanes typically consist of a 1-azabicyclooctane fused to pyrrolidine ring. The substituent heteroaryl groups are 5- or 6-membered ring heteroaromatics, such as 3-pyridinyl and 5-pyrimidinyl moieties, which are attached directly to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine moiety is substituted with an arylcarbonyl (amide type derivative) or an arylaminocarbonyl (N-arylcarbamoyl) (urea type derivative) group. The compounds are beneficial in therapeutic applications requiring a selective interaction at certain nAChR subtypes. That is, the compounds modulate the activity of certain nAChR subtypes, particularly the α7 nAChR subtype, and do not have appreciable activity toward muscarinic receptors. Radiolabeled versions of the compounds can be used in diagnostic methods.

  本发明涉及杂环取代的二氮杂三环烷的酰胺和脲衍生物，包括这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。更具体地说，治疗方法涉及通过给予一种或多种化合物来调节α7 nAChR亚型的活性，以治疗或预防α7 nAChR亚型介导的疾病。二氮杂三环烷通常由1-氮杂双环辛烷和吡咯烷环融合而成。取代杂环基团是5-或6-成员环杂芳基，例如3-吡啶基和5-嘧啶基，直接连接到二氮杂三环烷上。吡咯烷基的次级氮原子被芳基羰基（酰胺型衍生物）或芳基氨基羰基（N-芳基氨基甲酰）（脲型衍生物）基团取代。这些化合物对于需要在某些nAChR亚型上选择性作用的治疗应用是有益的。也就是说，这些化合物调节特定的nAChR亚型，特别是α7 nAChR亚型的活性，并且对于胆碱能受体没有明显的活性。这些化合物的放射性标记版本可用于诊断方法。
• TREATMENT WITH ALPHA7 SELECTIVE LIGANDS
  申请人：Bencherif Merouane

  公开号：US20110262407A1

  公开（公告）日：2011-10-27

  The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.

  本发明涉及用于治疗或预防刺激神经发生增殖有益的疾病和紊乱的方法、用途和选择性α7 nAChR配体。即，其中神经发生增殖的招募是治疗性的。
• TREATMENT WTH ALPHAT SELECTIVE LIGANDS
  申请人：TARGACEPT, INC.

  公开号：US20140234270A1

  公开（公告）日：2014-08-21

  The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.

  本发明涉及方法、用途和选择性α7 nAChR配体，用于治疗或预防刺激神经发生的疾病和障碍，即通过招募神经发生来进行治疗的疾病和障碍。
• Treatment with alpha7-selective ligands
  申请人：Targacept, Inc.

  公开号：EP2409703A1

  公开（公告）日：2012-01-25

  The present invention relates to selective α7 nAChR agonist compounds for use in treating or preventing metabolic syndrome.

  本发明涉及用于治疗或预防代谢综合征的选择性 α7 nAChR 激动剂化合物。